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Mutations in Epigenetic Regulation Genes
Are a Major Cause of Overgrowth
with Intellectual Disability
Katrina Tatton-Brown,1,2 Chey Loveday,1 Shawn Yost,1 Matthew Clarke,1 Emma Ramsay,1
Anna Zachariou,1 Anna Elliott,1 Harriet Wylie,1 Anna Ardissone,3 Olaf Rittinger,4 Fiona Stewart,5
I. Karen Temple,6,7 Trevor Cole,8 Childhood Overgrowth Collaboration, Shazia Mahamdallie,1
Sheila Seal,1 Elise Ruark,1 and Nazneen Rahman1,9,10,*
To explore the genetic architecture of human overgrowth syndromes and human growth control, we performed experimental and bio-
informatic analyses of 710 individuals with overgrowth (height and/or head circumferenceRþ2 SD) and intellectual disability (OGID).
We identified a causal mutation in 1 of 14 genes in 50% (353/710). This includesHIST1H1E, encoding histone H1.4, which has not been
associated with a developmental disorder previously. The pathogenicHIST1H1Emutations are predicted to result in a product that is less
effective in neutralizing negatively charged linker DNA because it has a reduced net charge, and in DNA binding and protein-protein
interactions because key residues are truncated. Functional network analyses demonstrated that epigenetic regulation is a prominent
biological process dysregulated in individuals with OGID. Mutations in six epigenetic regulation genes—NSD1, EZH2, DNMT3A,
CHD8, HIST1H1E, and EED—accounted for 44% of individuals (311/710). There was significant overlap between the 14 genes involved
in OGID and 611 genes in regions identified in GWASs to be associated with height (p ¼ 6.84 3 108), suggesting that a common
variation impacting function of genes involved in OGID influences height at a population level. Increased cellular growth is a
hallmark of cancer and there was striking overlap between the genes involved in OGID and 260 somatically mutated cancer driver genes
(p ¼ 1.75 3 1014). However, the mutation spectra of genes involved in OGID and cancer differ, suggesting complex genotype-pheno-
type relationships. These data reveal insights into the genetic control of human growth and demonstrate that exome sequencing in
OGID has a high diagnostic yield.Introduction
Human growth control, at the organismal and cellular
level, is a complex process essential for health and
dysregulated in many developmental disorders and
cancers. The mechanistic control of cell size and prolif-
eration has been studied, by diverse approaches, in
many different species.1,2 However, the control of
overall size of an organism has been relatively under-
studied and is still poorly understood. The study of
human growth disorders therefore not only improves
diagnosis and management of human disease, it also
offers an opportunity to enhance knowledge about
the fundamental processes governing control of human
size.
Human overgrowth syndromes are a nebulous group
of conditions defined as having height and/or head
circumferenceR2 SD above the mean, together with addi-
tional phenotypic abnormalities, the most common of
which is intellectual disability.3 Overgrowth syndromes
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mutations, imprinting disruption, and chromosome
dosage abnormalities.3,4
Single-gene disorders associated with overgrowth and in-
tellectual disability (OGID) are well recognized; Sotos syn-
drome (MIM: 117550) and Weaver syndrome (MIM:
277590) are prototypic examples, due to NSD1 (MIM:
606681) and EZH2 (MIM: 601573) mutations, respectively
(see GeneReviews by Tatton-Brown et al. in Web
Resources).5 OGID syndromes have been increasingly
identified over the last decade.3,4 The advent of next-gen-
eration sequencing has been the foremost reason for this
progress and has allowed elucidation of the genetic causes
of clinically established syndromes and the delineation of
new syndromes.5–12
Despite these advances, many individuals with OGID
remain without a genetic diagnosis. In addition, the rela-
tive contribution of the different genes to OGID is un-
known. To better characterize the genetic landscape of
OGID, we have here studied 710 affected individuals
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Subjects and Methods
Subjects
We recruited participants through the Childhood Over-
growth (COG) Study, which began recruitment in 2005,
approved by the London Multicenter Ethics Committee
(05/MRE02/17). Informed consent was obtained from all
participants and/or parents, as appropriate. Individuals
were eligible for this study if they had height and/or
head circumference at least two standard deviations above
the mean (Rþ2 SD, UK90 growth data)13 at some point in
childhood, together with intellectual disability. We have
termed this condition OGID (overgrowth þ intellectual
disability). Overgrowth phenotypes that are not associated
with intellectual disability, such as Beckwith Wiedemann
syndome (MIM: 130650) or Marfan syndrome (MIM:
154700), were not included. Regional or asymmetric
overgrowth phenotypes (e.g., hemihypertrophy) in the
absence of increased height or head circumference were
not included.
710 individuals with OGID were included. 97% (693)
were recruited to the study from clinical genetics depart-
ments. For 323 individuals, samples from both parents
were also available and included. 205 probands had
both height and head circumference Rþ2 SD, termed
‘‘headþheight’’ in Table S1. 138 had height Rþ2 SD with
OFC <2 SD, termed ‘‘height only’’ and 109 had
OFC Rþ2 SD and height <2 SD, termed ‘‘head only.’’ For
the remaining 258 individuals, the child was recruited to
the study because they had overgrowth, but measurements
for both height and head were not provided. The over-
growth category is termed ‘‘unspecified’’ for these case sub-
jects in Table S1. Intellectual disability was classified by the
referring clinician as severe (77 case subjects), moderate
(228 case subjects), or mild (229 case subjects). The referrer
did not state the severity of the OGID for 176 individuals
(termed ‘‘unspecified’’ in Table S1).Control Data
We used the Exome Aggregation Consortium (ExAC) data
v.3 accessed on 13/11/2015 (excluding the TCGA sam-
ples)14 and the ICR1000 UK exome series15 as reference
data. We generated and analyzed the ICR1000 UK exome
series data using the same sequencing and analysis pipe-
line described for the OGID samples.Targeted Gene Analyses
We previously reported mutations in NSD1, EZH2,
DNMT3A (MIM: 602769), and PPP2R5D (MIM: 601646)
in 198 case subjects. The relevant references are in Table
S1. Intragenic mutations in these genes were detected
with Sanger sequencing. NSD1 is unusual among the 14
OGID genes included in this study in being prone to dele-
tion by a 2 Mb 5q35 microdeletion, mediated by flanking
low-copy repeats.16 We used MLPA to identify 5q35
microdeletions encompassing NSD1.17 NSD1 MLPA is726 The American Journal of Human Genetics 100, 725–736, May 4,also capable of detecting exon CNVs that account for
5% of NSD1 mutations.17 Microdeletions and exon
CNVs in the other genes were not sought, but are unlikely
to be a major contributor because the surrounding
sequence architecture and/or mechanism of pathogenicity
make it much less likely that such events will cause OGID.Exome Sequencing
We performed exome sequencing in all probands in whom
no mutation had been identified by targeted gene analyses
and in parental samples where available. We performed
exome sequencing using the Nextera Rapid Capture
Exome Kit (Illumina). We prepared libraries from 50 ng
genomic DNA using the Nextera DNA Sample Preparation
Kit (Illumina). On average 33M reads mapped to the pull-
down and 86% of targeted bases had R153 coverage.
The captured libraries were PCR amplified using the sup-
plied paired-end PCR primers. Exome sequencing in 57
samples was performed before the Nextera Exome Kit
was available using the TruSeq Exome Enrichment Kit,
which includes the 14 genes involved in OGID. When
converting our exome pipeline from TruSeq to Nextera,
we undertook in-house evaluation and validation to
ensure that the performance was equivalent. Sequencing
was performed on an llumina HiSeq 2000 or HiSeq 2500
(high output mode) using v3 chemistry and generating
2 3 101 bp reads.Variant Calling
We used the OpEx v1.0 pipeline to perform variant call-
ing.18 We converted raw data to FASTQs using CASAVA
v.1.8.2 with default settings. The OpEx v1.0 pipeline uses
Stampy19 to map to the human reference genome, Picard
to flag duplicates, Platypus20 to call variants, and CAVA21
to provide consistent annotation of variants with the
HGVS-compliant CSN (Clinical Sequencing Notation)
standard v1.0.21 The transcript information for variant
annotation for the 14 relevant genes are given in Table 1.Variant Prioritization and Validation
We excluded variants with MAF > 0.5% in either the
Exome Aggregation Consortium (ExAC) and/or the
ICR1000 UK exome series. For the de novo analyses, we
identified and validated any high-quality (as defined by
OpEx18) variant in the child that was not present in either
parent. We evaluated and validated all rare variants identi-
fied in the 14 genes.
We confirmed all small variants in Table S1 that were
called in exomes via Sanger sequencing of M13-tagged
PCR products generated from genomic DNA. We per-
formed PCR using the QIAGEN Multiplex PCR Kit accord-
ing to the manufacturer’s instructions. We sequenced PCR
products using M13 sequencing primers, the BigDye
Terminator Cycle Sequencing Kit, and an ABI 3730 Genetic
Analyzer (Applied Biosystems). We analyzed sequences
using Mutation Surveyor software v.3.20 (SoftGenetics)2017
Table 1. Gene and Transcript Information for 14 Genes Involved in OGID
Gene MIM Number HGNC ID Ensembl Transcript RefSeq Transcript
AKT3 611223 HGNC:393 ENST00000366539 NM_005465
BRWD3 300553 HGNC:17342 ENST00000373275 NM_153252
CHD8 610528 HGNC:20153 ENST00000399982 NM_001170629
DNMT3A 602769 HGNC:2978 ENST00000264709 NM_175629
EED 605984 HGNC:3188 ENST00000263360 NM_003797
EZH2 601573 HGNC:3527 ENST00000320356 NM_004456
GPC3 300037 HGNC:4451 ENST00000370818 NM_004484
HIST1H1E 142220 HGNC:4718 ENST00000304218 NM_005321
MTOR 601231 HGNC:3942 ENST00000361445 NM_004958
NFIX 164005 HGNC:7788 ENST00000360105 NM_002501
NSD1 606681 HGNC:14234 ENST00000439151 NM_022455
PIK3CA 171834 HGNC:8975 ENST00000263967 NM_006218
PPP2R5D 601646 HGNC:9312 ENST00000485511 NM_006245
PTEN 601728 HGNC:9588 ENST00000371953 NM_000314and verified the outputs bymanual inspection by two indi-
viduals, independently.Pathogenic Mutation Determination
Apart from HIST1H1E (MIM: 142220), we considered a
variant in the other 13 genes to be pathogenic if it fulfilled
one or more of the following criteria. (1) It was a de novo
mutation in a gene for which such de novo mutations
were already proven to cause OGID. (2) The inheritance
was unknown, because parental samples were unavailable,
but it had been previously identified as a pathogenic de
novo mutation in OGID. (3) It was a protein-truncating
variant ([PTV] frameshifting indels, stop-gain, or essential
splice-site variants) in a gene in which truncating muta-
tions have been proven to be pathogenic. (4) There was
clear evidence from the literature that it was pathogenic.
The evidence for HIST1H1E mutations being pathogenic
is provided in the Results.HIST1H1E Statistical Analyses
We used the methods described in the DDD study22 to
calculate the probability of identifying four de novo frame-
shift mutations in HIST1H1E using the gene-specific muta-
tion rates from Samocha et al.23 The frameshift mutation
rate in HIST1H1E (4.18 3 107) was multiplied by twice
the number of case subjects in this study (710) in order
to get the expected number of frameshift mutations. We
calculated the probability of observing four or more de
novo frameshift mutations in HIST1H1E given the ex-
pected number of frameshift mutations via the ppois func-
tion in R.
We modeled the significance of mutation clustering in
HIST1H1E under a binomial distribution where the proba-The Amebility of observing a mutation in a 12 bp region, which
comprises 1.8% of the coding sequence, was 0.018.
Protein Net Charge Calculation
We obtained wild-type HIST1H1E cDNA (frame 1)
sequence from Ensembl (ENST00000304218.5). We gener-
ated the HIST1H1E cDNA sequences edited with OGID
mutations (frame 2). We used the variant c.430delG to
generate the other possible alternative reading frame in
HIST1H1E (frame 3). We translated the cDNA sequences
using the Translate Tool at ExPASy. We calculated the net
charge of the carboxy-terminal domain, from p.Lys110 on-
ward, at neutral pH using the Peptide Property Calculator
at the Innovagen website.
Functional Network Analyses
We performed functional enrichment analysis using g:Pro-
filer (v.r1665_e85_eg32).24 We used the 14 genes in Table 1
as our query set. We looked for enrichment among Gene
Ontology molecular function terms and KEGG pathway
gene sets, requiring the size of the functional category to
be between 5 and 500 genes and using the Benjamini-
Hochberg false discovery rate as the significance threshold.
The FDR q values presented are the Benjamini-Hochberg
critical values.
Phenotypic Analyses
We tested for significant difference in the diagnostic yields
between different phenotypic groups using the prop.test
function in R. We calculated the significance of association
between an individual havingmacrocephaly and their mu-
tation status (either a mutation in a PI3K/AKT pathway
gene or a mutation in an epigenetic regulation gene) using
a Fisher’s exact test, which we implemented with therican Journal of Human Genetics 100, 725–736, May 4, 2017 727
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Figure 1. Causal Mutation Identified in 50% of OGID Probands
Proportion of pathogenic mutations identified in 710 individuals
with OGID. Epigenetic regulation genes (red), including NSD1
which is the predominant gene, constitute the major gene set.
PI3K/AKT pathway genes (blue) also significantly contribute to
OGID.fisher.test function in R. We calculated the significance of
association between an individual having macrocephaly
in the absence of increased height and their mutation
status, and the significance of association between an indi-
vidual having increased height in the absence of macroce-
phaly and their mutation status in the same way.We tested
for significant difference in the proportion of individuals
with mild intellectual disability for those with a mutation
in a PI3K/AKT pathway OGID gene and those with a muta-
tion in an epigenetic regulation OGID gene using the
prop.test function in R.Height GWAS Gene and Cancer Driver Gene
Comparisons
We obtained the list of 611 genes located in regions associ-
ated with human height through GWASs from Table S1 of
Wood et al.25 We obtained a list of 260 somatically
mutated cancer genes from Table S2 of Lawrence et al.26
and the somatic mutations from the tumor portal website.
We calculated the probability of seeing the observed
overlap of the OGID gene set with the GWAS gene set un-
der a hypergeometric probability distribution assuming a
total hypothetical size of 20,000 protein-coding genes in
the exome using the phyper function in R. We calculated
the probability of seeing the observed overlap of
OGID gene set with the cancer driver gene set in the
same way.Results
Contribution of Gene Mutations to OGID
Using exome or targeted gene analyses, we identified a
pathogenic mutation in one of 14 genes in 357 individuals
with OGID, giving a diagnostic yield of 50% (Figure 1).728 The American Journal of Human Genetics 100, 725–736, May 4,By far the most common cause was a mutation in NSD1
(240 cases, 34%), followed by EZH2 (34, 4.8%), DNMT3A
(18, 2.5%), PTEN (MIM: 601728) (16, 2.3%), NFIX (MIM:
164005) (14, 2.0%), CHD8 (MIM: 610528) (12, 1.7%),
BRWD3 (MIM: 300553) (7, 1.0%), HIST1H1E (5, 0.7%),
PPP2R5D (3, 0.4%), (2 cases each) EED (MIM: 605984),
GPC3 (MIM: 300037), and MTOR (MIM: 601231), and
(1 case each) AKT3 (MIM: 611223) and PIK3CA (MIM:
171834) (Table S1). Among the 323 parent-proband trios,
we identified a cause in 191 (59%) of which 179 were
de novo mutations and 12 were inherited.
Our data allow confirmation that EED mutations cause
OGID. Two case reports of individuals with a characteristic
phenotype that includes overgrowth have been pub-
lished.10,27 We here present two additional cases with a
de novo EED mutation. The individuals have the same
facial phenotype to each other and to previously reported
case subjects, with long, narrow palpebral fissures, telecan-
thus, and retrognathia. Notably, EED is a direct binding
partner of EZH2,28 which has an established role in
causing OGID.29 Some role in overgrowth was either
known, or has been proposed, for the remainder of
these, apart from HIST1H1E (see GeneReviews by Eng in
Web Resources).6,9,10,12,29–35
HIST1H1E Mutations Cause OGID
We present here data showing that certain HIST1H1E
mutations cause OGID. Through exome sequencing
we identified five unrelated probands—COG0405,
COG0412, COG0552, COG1739, and COG1832—with
heterozygous HIST1H1E protein truncating variants
(PTVs) (Figure 2, Tables 1 and S1). In four probands the
PTV had arisen de novo. Parental samples were not avail-
able for the fifth child, but she carried the same mutation
as one of the children with a de novo mutation. The
detection of four de novo HIST1H1E mutations in 710 in-
dividuals is highly unlikely to have occurred by chance,
as determined from gene-specific de novo mutation rates
(p ¼ 5.17 3 1015). None of the mutations are present in
the ExAC dataset, nor in 11,677 exomes analyzed in-house
with similar pipelines. These results strongly support
HIST1H1E mutations as a cause of OGID.
HIST1H1E encodes histone H1.4. In humans, H1.4 is one
of 11 H1 linker histones that mediate the formation of
higher-order chromatin structures and regulate the accessi-
bility of regulatory proteins, chromatin remodelling fac-
tors, and histone-modifying enzymes to their target
sites.36,37 The five mutations we identified cluster signifi-
cantly (p ¼ 2.0 3 109) to a 12-bp region in the carboxy-
terminal domain (CTD) that is involved in chromatin
binding and protein-protein interactions (Figure 2A).36
PTVs in the intronless histones have been shown to evade
nonsense-mediated mRNA decay.38 Thus the OGID-
causing mutations are predicted to generate a truncated
product.
The CTD of linker histones regulate higher-order chro-
matin structure through neutralization of negatively2017
c.430dupG
c.436_458del23
c.441dupC
Frame     Mutation                         Sequence                                       Length  Charge
1    Wildtype        ...KKATGAATPKKSAKKTPKKAKKPAAAAGAKKAKSPKKAKAAKPKKAPKSPAKAKAVKPK...   219      44
2    c.430dupG       ...KKATGGGHPQEERQEDPKEGEEAGCSCWSQKSEKPEKGESSQAKKGAQEPSEGQSS         194      7
2    c.441dupC       ...KKATGAATPQEERQEDPKEGEEAGCSCWSQKSEKPEKGESSQAKKGAQEPSEGQSS         194      7
2    c.436_458del23  ...KKATGAA--------DPKEGEEAGCSCWSQKSEKPEKGESSQAKKGAQEPSEGQSS         186      9
3                    ...KKATGRPPPRRAPRRPQRRRRSRLQLLEPKKRKARKRRKQPSQKRRPRAQRRPKQLNPR...   227      48
NTD CTDGlobular domain
B COG0405 COG0412
1.5 years 13 years
C
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Figure 2. HIST1H1E Mutations Cause OGID
(A) HIST1H1Emutations cluster within 12 bp region in the carboxy-terminal domain (CTD) and have a similar predicted impact on pro-
tein function. The three different frameshift mutations generate the same open reading frame (frame 2), which is predicted to reduce the
length and net charge (at pH 7) of the CTD compared to the wild-type (frame 1). The other possible alternate reading frame (frame 3)
increases the protein length and net charge. Abbreviations: CTD, carboxy-terminal domain; NTD, amino-terminal domain.
(B–D) Facial images of three individuals with HIST1H1E mutations showing full cheeks and high hairline.charged linker DNA.36 The pathogenic HIST1H1E muta-
tions all result in the same shift in the reading frame
and are predicted to generate similar truncated proteins,
with a reduced net charge of 7–9 (compared to 44 for
the wild-type protein) (Figure 2A). The mutant protein is
thus likely to be less effective in neutralizing negatively
charged linker DNA. Moreover, the truncation of the
C-terminus likely impedes DNA binding and protein-pro-
tein interactions. It is also noteworthy that the other
possible alteration in reading frame would reduce neither
the net charge nor the length of the protein (Figure 2A).
Taken together, these data suggest that specific HIST1H1E
mutations, restricted in position and type, cause human
overgrowth.
HIST1H1E Clinical Phenotype
Individuals with HIST1H1E mutations had similar facial
appearance in childhood with full cheeks, high hairline,
and telecanthus (Figures 2B–2D). Height, head circumfer-The Ameence, and degree of intellectual disability were variable,
as were the additional clinical features. It is currently
unclear whether these additional features are HIST1H1E
associations or coincidental findings. Individual case de-
scriptions are below.
COG0405, a female individual, was born at term with
a weight of 3.58 kg (þ0.1 SD) and a length of 53 cm
(þ1.5 SD). She was floppy in the neonatal period. A brain
MRI scan at 4 months demonstrated mild ventricular dila-
tation but no other abnormalities. Her bone age at chrono-
logical age of 7 months was advanced to 18–24 months. By
19 months, her length was 87 cm (þ2.0 SD) with a weight
of 13.4 kg (þ1.8 SD) and she had developed a strabismus.
At 13 years of age, the individual was noted to have normal
growth with a height of 150.8 cm (0.6 SD), a head
circumference of 55.8 cm (0.5 SD), and a weight of
48.85 kg (þ0.4 SD). She has developed a severe kyphosco-
liosis for which she required surgery and has a mild intel-
lectual disability.rican Journal of Human Genetics 100, 725–736, May 4, 2017 729
COG0412, a male individual, was born at 1 week after
term following an uncomplicated pregnancy and delivery.
He weighed 4.75 kg (þ2.4 SD). In the neonatal period he
was noted to be floppy; he had poor feeding and unde-
scended testes. At 1.5 years he was very tall at 105 cm
(þ8.3 SD) with a weight of 18.8 kg (þ4.6 SD) and a head
circumference of 52.5 cm (þ2.6 SD). He was reported to
have multiple nevi and redundant skin on the palms of
his hands. He had a moderate intellectual disability and
no behavioral issues at that time. When he was reviewed
at 15.5 years, he was no longer tall with a height of
166.5 cm (0.6 SD). His head circumference was 58.7 cm
(þ1.4 SD). By this age he had developed an anxiety disor-
der that was refractory to medical treatment. He had also
developed phobias. In addition, he had major dental prob-
lems with crumbling teeth and he had dry, flaky nails.
COG0552, a female individual, was born at term with a
weight of 4.79 kg (þ2.5 SD) and length of 57 cm (þ3.6 SD).
She was floppy in the neonatal period with poor feeding.
She developed no new medical problems in childhood.
At the age of 4.2 years she was reported to be delayed in
her development. She had a height of 108 cm (þ1.2 SD),
head circumference of 55 cm (þ3.2 SD), and weight of
24 kg (þ2.7 SD).
COG1739, a female individual, was initially thought
clinically to have Weaver syndrome. She was born at
37 weeks after an uncomplicated pregnancy and labor
with a weight of 3.25 kg (þ0.8 SD), length of 49 cm
(þ0.7 SD), and head circumference of 37 cm (þ3.3 SD).
She was hypoglycemic and hypertonic in the neonatal
period, and was also noted to have camptodactyly. At
1.9 years she was diagnosed with a moderate intellectual
disability and had a height of 85 cm (mean), head
circumference of 51 cm (þ1.8 SD), and weight of 12 kg
(0.3 SD).
COG1832, a male individual, was born at 1 week after
term weighing 3.74 kg (þ0.4 SD). The pregnancy had
been complicated by exposure to chicken pox. At birth,
COG1832 was noted to have talipes equinovarus and later
in the neonatal period was diagnosed with delayed visual
maturation. A brain MRI scan showed a slender corpus cal-
losum and unusual ventricular outline, possibly indicative
of a periventricular leukomalacia. At 8.5 years, height was
133.2 cm (þ0.5 SD) with a weight of 33 kg (þ1.2 SD). The
head circumference at 6.3 years was 59 cm (þ3.7 SD). He
has limited speech but with verbal comprehension
markedly ahead of this ability to express himself. He has
left amblyopia and astigmatism. His hearing is normal.
He suffers from constipation. At times his behavior is
challenging.
Functional Network Analyses
To investigate the biological processes abrogated by
OGID pathogenic mutations, we performed functional
enrichment analysis using theGOmolecular function terms
and KEGG pathway gene sets in g:Profiler.24 The chromatin
binding (FDRqvalue¼1.583106) andPI3K/AKTsignaling730 The American Journal of Human Genetics 100, 725–736, May 4,pathway (FDR q value¼ 6.803 105) gene sets were signifi-
cantly enriched.
Six genes—NSD1, EZH2, DNMT3A, EED, CHD8, and
HIST1H1E—were in the chromatin binding gene set.
All encode proteins involved in epigenetic regulation
(Figure 3A). NSD1 is a histone methyltransferase that cata-
lyzes methylation of H3K36, and to lesser extent H4K20,
and is primarily associated with transcriptional activa-
tion.39 EZH2 and EED are key components of the poly-
comb repressive complex 2 (PRC2), which catalyzes
methylation of H3K27, resulting in transcriptional re-
pression of target genes.28 DNMT3A is a DNAmethyltrans-
ferase crucial for the establishment of new methylation
marks during early embryogenesis and the sex-dependent
methylation of imprinted genes.40,41 CHD8 encodes an
ATP-dependent chromatin remodeler that binds to meth-
ylated H3K4, a key histone modification at active pro-
moters.35 As noted above, H1.4 binds to linker DNA
between nucleosomes and has key roles in chromatin
compaction and regulation of gene expression.37 Together,
mutations in these six genes accounted for 311 (44%) of
our series. Disruption of epigenetic regulation is therefore
a prominent molecular mechanism underlying OGID
(Figure 1).
Five of the genes—PTEN, AKT3, PIK3CA (which encodes
p110a, the catalytic domain of the heterodimeric PI3K lipid
kinase),MTOR, and PPP2R5D (which encodes B56d a regu-
latory subunit of the heterotrimeric PP2A protein phospha-
tase)—are in the PI3K/AKT pathway, which plays a key role
in the regulation of growth (Figure 3B). Activation of the
PI3K/AKT pathway results in cellular growth promotion
through increased cell metabolism, cell survival, cell turn-
over, and protein synthesis.42 Together mutations in
these genes made only a minor contribution to our OGID
series (23 case subjects, 3.2%). In part this is because indi-
viduals with mutations in these genes are more often diag-
nosed with other conditions, such as Cowden syndrome
(MIM: 158350), megalencephaly-capillary malformation
syndrome (MIM: 602501), or regional overgrowth (see
GeneReviews by Eng in Web Resources).34
The remaining three genes—NFIX, GPC3, and BRWD3—
encode a transcription factor, a proteoglycan, and a bro-
modomain-containing protein, respectively6,31,32 (23 case
subjects, 3.2%). There is currently no clear functional
link between these genes and the other genes we report
here. However, it is possible that BRWD3 mutations also
cause overgrowth through epigenetic regulation dysfunc-
tion, as there are data suggesting it is involved in histone
H3.3 regulation.43
Phenotype Analyses
There was enrichment of mutations in individuals with
both increased height and head circumference, compared
to individuals in whom only one growth parameter was
increased, as would be expected. Specifically the diagnostic
yield in individuals with bothmacrocephaly and increased
height was 59% (120/205), significantly higher than the2017
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Figure 3. Schematic of Key Biological
Processes Impacted in OGID
(A) Epigenetic regulation. NSD1, EED, and
EZH2 directly methylate specific histone
tail lysine residues. DNMT3A is a de
novo DNA methyltransferase and CHD8
is a chromatin remodeling complex pro-
tein that binds methylated lysine 4 of his-
tone H3. H1.4 (encoded byHIST1H1E) sta-
bilizes higher-order chromatin structures.
(B) All OGID mutations are predicted to
lead to reduced function PI3K/AKT
pathway. The PI3K/AKT pathway posi-
tively regulates growth. AKT3, MTOR,
and p110a (encoded by PIK3CA) are
pathway activators. PTEN and B56d (en-
coded by PPP2R5D) are pathway suppres-
sors. OGID mutations in AKT3, MTOR,
and PIK3CA are activating, whereas
OGID mutations in PTEN and PPP2R5D
are inactivating.diagnostic yields in individuals with only macrocephaly
(43%, 47/109, p ¼ 0.006) or only increased height (45%,
62/138, p ¼ 0.009). There was no significant difference
between the diagnostic yields in individuals with only
macrocephaly and in those with only increased height
(p ¼ 0.146). There was also no significant difference be-
tween the diagnostic yield in individuals with unspecified
growth parameters (50%, 130/258) and any other group.
To further explore the phenotypic spectrum of OGID, we
compared the growth and intellectual disability severity of
the individualsdue tomutations in theepigenetic regulation
genes and those involved in the PI3K/AKT pathway, using
case subjects forwhich the relevantphenotypic information
was available (217 individuals with complete growth data
and 263 individuals with intellectual disability severity in-
formation) (Figure 4). Macrocephaly (i.e., head circumfer-
enceR2 SD above the mean) occurred more frequently in
individuals with PI3K/AKT pathway gene mutations; all 17
had macrocephaly, compared with 140/200 individuals
with OGID due to epigenetic regulation gene mutations
(p ¼ 4.13 103; Figure 4A). Furthermore, 9/17 of the PI3K/
AKT pathway case subjects had macrocephaly without
increased height compared with 32/200 of the epigenetic
regulation pathway cases (p¼ 1.03 103; Figure 4A). The re-
maining 60/200 had increased height without macroce-
phaly, a combination not present in OGID due to PI3K/
AKT pathway gene mutations (p ¼ 4.1 3 103; Figure 4A).The American Journal of HumanVarying severity of intellectual dis-
ability was a feature of both groups,
but mild intellectual disability was
more common in OGID due to PI3K/
AKT pathway gene mutations (14/20)
than OGID due to epigenetic re-
gulation gene mutations (101/243;
p ¼ 0.01) (Figure 4B).
The risk of childhood cancer is one
the most controversial areas of OGIDmanagement. 8/710 OGID-affected individuals in this
study developed cancer in childhood (Table S1). This in-
cludes 4/357 with an identified genetic cause, three of
whom had an EZH2 mutation. COG1724 developed neu-
roblastoma at 46 months, COG0285 developed T cell
non-hodgkins lymphoma at 13 years, and COG1521 was
diagnosed with both neuroblastoma and acute lympho-
blastic leukemia at 13 months. The childhood cancer inci-
dence for EZH2mutation carriers in this study was thus 9%
(3/34). The remaining child had an NSD1 microdeletion
and T cell non-hodgkins lymphoma. This information
will be useful in family discussions about childhood cancer
risk, particularly in relation to surveillance strategies,
which are generally of unproven benefit and can be associ-
ated with appreciable false positive rates.44
Height GWAS Loci Comparative Analyses
We next explored the overlap between the 14 genes and
611 genes implicated through genome-wide association
studies (GWASs) to be involved in the control of human
height.25 There was significant overlap; six genes involved
in OGID were also present in height GWAS regions (p ¼
6.8 3 108) (Figure S1). The overlap is primarily through
the epigenetic regulation genes, all of which (except
EED) were represented in height GWAS regions. Two sepa-
rate intronic SNPs in each of NSD1 and DNMT3A were
independently associated with height in the GWAS andGenetics 100, 725–736, May 4, 2017 731
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Figure 4. Phenotypic Differences be-
tween OGID due to Mutations in Epige-
netic Regulation Genes Compared to
PI3K/AKT Pathway Genes
Comparison of the distribution of (A)
overgrowth categories and (B) degree of
intellectual disability in case subjects
with epigenetic regulation gene muta-
tions (red) compared with PI3K/AKT
pathway gene mutations (blue).there were no other genes within the linkage disequilib-
rium (LD) blocks of association. This strongly suggests
that NSD1 and DNMT3A functional impact underlie the
height association in these regions (Figure S1). Single
SNPs in intron 5 of CHD8, intron 9 of MTOR, 1 kb down-
stream of HIST1H1E, and 48 kb upstream of EZH2 were
also associated with height.25 For HIST1H1E and EZH2,
there were no other genes in the LD block of association.
For MTOR the variant associated with a cis-eQTL affecting
MTOR expression, though the association was better ac-
counted for by an upstream variant (rs2295080) in the
MTOR promoter region that was in LD with the height
SNP (LD r2 ¼ 0.85).25 Although the causal SNPs and mech-
anisms of association are not fully elucidated, these data
suggest that common variation in some genes involved
in OGID also influence height at a population level.
Cancer Somatic Driver Mutation Comparative Analyses
Dysregulated cellular growth is a hallmark of cancer, and
certain human conditions are associated with both over-
growth and increased cancer risk (see GeneReviews by
Eng in Web Resources).45 We therefore next sought to
investigate the overlap between the 14 genes and 260 so-
matically mutated cancer driver genes reported by Law-
rence et al.26 There was significant overlap; 8/14 genes
involved in OGID were somatically mutated in a diverse
range of cancers (NSD1, EZH2, DNMT3A, PTEN, CHD8,
HIST1H1E, MTOR, PIK3CA; p ¼ 1.7 3 1014). For the
PI3K/AKT pathway genes, the mutation spectra are similar
in OGID and cancer.34 By contrast, for the epigenetic regu-
lation genes, the mutation spectra in OGID and cancer
have substantial, distinctive differences.
Somatic mutations in HIST1H1E, EZH2, and DNMT3A
occur in hematological malignancies.26,46–50 HIST1H1E
and EZH2 mutations are each present in 20% of B cell
lymphomas.48,49 Somatic HIST1H1E mutations are nonsy-
nonymous mutations throughout the gene and do not
include the clustered PTVs that cause OGID (Figure 5).732 The American Journal of Human Genetics 100, 725–736, May 4, 2017EZH2mutations in B cell lymphomas
are often activating nonsynonymous
mutations in the SET domain, the
majority of which target a single
amino acid, p.Tyr646.48 Nonsynony-
mous mutations at this residue have
not been detected in OGID and are
not present in ExAC, perhaps sug-gesting that germline EZH2 mutations altering p.Tyr646
are not compatible with life (Figure 5). Inactivating EZH2
mutations are present in myeloid malignancies and in T-
ALL.46–48 A proportion of these latter mutations overlap
with EZH2 mutations in OGID.
DNMT3A is one of the most frequently mutated genes in
AML and mutations also occur less frequently in other he-
matological malignancies.26,50 The majority target a single
residue, p.Arg882, with the remainder being nonsynony-
mous variants and PTVs scattered through the gene. Muta-
tions at p.Arg882 have not thus far been reported in OGID
(Figure 5). Protein modeling suggests that the somatic mu-
tations primarily impact DNA binding, whereas the muta-
tions in OGID are more likely to impact histone binding.12
Somatic NSD1 mutations are seen in 10% of head and
neck squamous cell carcinomas26,51 and somatic CHD8
mutations are present in 3% of glioblastoma multiforme
(GBM).26 For these cancers the mutation pattern is similar
to that observed in OGID, with PTVs being the most
frequent mutation type (Figure 5).30 Interestingly, Law-
rence et al. found NSD1 and CHD8 to each be significant
in their pan-cancer analysis, present in 2% of cancers.26
However, the pan-cancer mutation spectra for each gene
was different to that observed in OGID, with most being
nonsynonymous mutations scattered throughout the
gene (Figure 5).Discussion
We present here the largest genetic study of overgrowth
and intellectual disability performed to date, including
710 affected individuals and 636 parents. We show that
OGID is a highly heterogeneous condition, involving at
least 14 genes. Perturbation of epigenetic regulation is a
prominent mechanism causing OGID and can be caused
bymutations in at least six different genes.NSD1mutation
is by far the most frequent cause of OGID, accounting for
Nonsynonymous Protein truncating variant (PTV)
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Figure 5. Mutations in Epigenetic Regu-
lation Genes in OGID and Cancers
Protein schematics showing the position
of mutations in HIST1H1E, EZH2,
DNMT3A, NSD1, and CHD8 in OGID
(below the gene) and specific cancers
(above the gene). The somatic cancer
driver mutations are from Lawrence
et al.26 Abbreviations are as follows:
AML, acute myeloid leukemia; CLL,
chronic lymphocytic leukemia; DLBCL,
diffuse large B-cell lymphoma; GBM, glio-
blastoma multiforme; HNSC, head and
neck squamous cell carcinoma; OGID,
overgrowth-intellectual disability.240 (34%) of our series. Notably, NSD1 is within a 2 Mb
region flanked by low-copy repeats thatmediate amicrode-
letion, which is one of the commonest causes of Sotos syn-
drome16 and was present in 29 individuals. Furthermore,
exon deletions or duplications (exon CNVs) are reported
in 5% of case subjects17 and were present in 9 individ-
uals. We analyzedNSD1 for these types of mutations, using
MLPA, as they are not robustly identifiable in our exome
data. We did not examine the other genes for microdele-
tions or exon CNVs. However, they are not known to be
a major contributor to pathogenic mutations in the other
genes. Even after excluding microdeletions and exon
CNVs, NSD1 is still the most common cause of OGID, ac-
counting for 202 (28%) of our series.
The comparative analyses of genes involved in OGID
with GWAS height loci and with cancer driver genes high-
light intriguing similarities and differences. Our data
strongly suggest that common variation impacting epige-
netic regulation of gene function influences height at a
population level. Further investigation of these GWAS
loci would be of considerable interest, particularly in rela-
tion to advancing knowledge on how, and why, epigenetic
regulation dysfunction impacts human growth.
Several genes involved in OGID are somatically mutated
in a diverse range of cancers, but the spectra of mutations,
particularly in the epigenetic regulation genes, is different
in OGID and cancer. The underlying reasons for these dif-
ferences will be complex and may include embryonic
lethality of certain oncogenic mutations when they occur
in the germline. Integration of germline and somaticmuta-
tional data in future research will be useful, and will likelyThe American Journal of Humanadvance functional and mechanistic
understanding of the genes.
One of the most striking results of
this study is the high diagnostic yield
of genetic testing in OGID; a genetic
cause was identified in 50% (357/
710) of case subjects. This is likely to
be an underestimate as we have
been conservative in attributing
pathogenicity to OGID gene variants
and additional OGID genes almostcertainly exist. Indeed, among the 132 trios in whom a
definitive cause was not found, a de novo mutation
possibly associated with their phenotype was present in
28; for example, two had de novo nonsynonymous vari-
ants in XRN1.
The diagnostic yield in our OGID series is higher than
exome-sequencing studies in other phenotypes that
include intellectual disability, which ranged from 13% to
35%.22,52–56 The studies are not directly comparable, as
most other exome studies included case subjects in which
prior genetic testing was negative. Our study recruitment
started prior to the discovery and clinical testing of most
of the genes we report here, which allows us to provide a
much better estimate of the overall contribution of rare
gene mutations to this phenotype.
Given the high success rate, strong consideration should
begiven tousingexome sequencingas afirst-linediagnostic
test in OGID. Height and head circumference can be
easily measured and intellectual disability is readily diag-
nosable. Therefore, implementation of exome sequencing
in OGID should be straightforward. Gene testing would
provide important diagnostic and recurrence risk infor-
mation to many families. Furthermore, it would increase
genotype-phenotype data, which are urgently required
to improve prognostic information. Of equal importance,
exome sequencing inOGIDwould lead to the identification
of new genes and new mutations in known genes. In
turn, this will stimulate and facilitate scientific research,
enhancing knowledge of basic biological processes control-
ling growth and the diverse pathologies in which human
growth control is dysfunctional.Genetics 100, 725–736, May 4, 2017 733
Supplemental Data
Supplemental Data include one figure, one table, and Supple-
mental Note and can be found with this article online at http://
dx.doi.org/10.1016/j.ajhg.2017.03.010.Acknowledgments
We thank the families for their participation and the clinicians
that recruited them. The full list of collaborators is in the Supple-
mental Note. We are grateful to Margaret Warren-Perry for
assistance in recruitment. We are grateful to Sandra Hanks, Silvana
Powell, Imran Uddin, and Ann Strydom for technical and
administrative support and Tara Mills for assistance with the
GWAS analyses. We acknowledge support from the NIHR RM/
ICR Biomedical Research Centre and Wessex NIHR clinical
research network. K.T.-B. is supported by funding from the
Child Growth Foundation (GR01/13). This work was supported
by Wellcome Trust Award 100210/Z/12/Z.
Received: December 7, 2016
Accepted: March 24, 2017
Published: April 27, 2017Web Resources
ExAC Browser, http://exac.broadinstitute.org/
ExPASy Translate Tool, http://web.expasy.org/translate/
g:Profiler, http://biit.cs.ut.ee/gprofiler/
GenBank, http://www.ncbi.nlm.nih.gov/genbank/
GeneReviews, Eng, C. (1993). PTEN hamartoma tumor syndrome.
https://www.ncbi.nlm.nih.gov/books/NBK1488/
GeneReviews, Tatton-Brown, K., Cole, T.R.P., and Rahman, N.
(1993). Sotos syndrome. https://www.ncbi.nlm.nih.gov/books/
NBK1479/
ICR1000 UK Exome Series, http://www.icr.ac.uk/icr1000exomes
OMIM, http://www.omim.org/
OpEx NGS Pipeline, http://www.icr.ac.uk/opex
Picard, http://broadinstitute.github.io/picard/
Protein calculator, http://pepcalc.com/protein-calculator.php
TumorPortal, http://www.tumorportal.org/References
1. Stocker, H., and Hafen, E. (2000). Genetic control of cell size.
Curr. Opin. Genet. Dev. 10, 529–535.
2. Saucedo, L.J., and Edgar, B.A. (2002). Why size matters:
altering cell size. Curr. Opin. Genet. Dev. 12, 565–571.
3. Tatton-Brown, K., and Weksberg, R. (2013). Molecular mecha-
nisms of childhood overgrowth. Am. J. Med. Genet. C. Semin.
Med. Genet. 163C, 71–75.
4. Edmondson, A.C., and Kalish, J.M. (2015). Overgrowth syn-
dromes. J. Pediatr. Genet. 4, 136–143.
5. Tatton-Brown, K., Murray, A., Hanks, S., Douglas, J., Arm-
strong, R., Banka, S., Bird, L.M., Clericuzio, C.L., Cormier-
Daire, V., Cushing, T., et al.; Childhood Overgrowth
Consortium (2013). Weaver syndrome and EZH2 mutations:
Clarifying the clinical phenotype. Am. J. Med. Genet. A.
161A, 2972–2980.
6. Malan, V., Rajan, D., Thomas, S., Shaw, A.C., Louis Dit Picard,
H., Layet, V., Till, M., van Haeringen, A., Mortier, G., Nampoo-
thiri, S., et al. (2010). Distinct effects of allelic NFIX mutations734 The American Journal of Human Genetics 100, 725–736, May 4,on nonsense-mediated mRNA decay engender either a Sotos-
like or a Marshall-Smith syndrome. Am. J. Hum. Genet. 87,
189–198.
7. Gibson, W.T., Hood, R.L., Zhan, S.H., Bulman, D.E., Fejes, A.P.,
Moore, R., Mungall, A.J., Eydoux, P., Babul-Hirji, R., An, J.,
et al.; FORGE Canada Consortium (2012). Mutations in
EZH2 cause Weaver syndrome. Am. J. Hum. Genet. 90,
110–118.
8. Cordeddu, V., Redeker, B., Stellacci, E., Jongejan, A., Fragale,
A., Bradley, T.E., Anselmi, M., Ciolfi, A., Cecchetti, S., Muto,
V., et al. (2014). Mutations in ZBTB20 cause Primrose syn-
drome. Nat. Genet. 46, 815–817.
9. Loveday, C., Tatton-Brown, K., Clarke, M., Westwood, I., Ren-
wick, A., Ramsay, E., Nemeth, A., Campbell, J., Joss, S., Gard-
ner, M., et al.; Childhood Overgrowth Collaboration (2015).
Mutations in the PP2A regulatory subunit B family genes
PPP2R5B, PPP2R5C and PPP2R5D cause human overgrowth.
Hum. Mol. Genet. 24, 4775–4779.
10. Cohen, A.S., and Gibson, W.T. (2016). EED-associated over-
growth in a second male patient. J. Hum. Genet. 61, 831–834.
11. Baynam, G., Overkov, A., Davis, M., Mina, K., Schofield, L.,
Allcock, R., Laing, N., Cook, M., Dawkins, H., and Goldblatt,
J. (2015). A germlineMTORmutation in Aboriginal Australian
siblings with intellectual disability, dysmorphism, macroce-
phaly, and small thoraces. Am. J. Med. Genet. A. 167, 1659–
1667.
12. Tatton-Brown, K., Seal, S., Ruark, E., Harmer, J., Ramsay, E., Del
Vecchio Duarte, S., Zachariou, A., Hanks, S., O’Brien, E., Aks-
glaede, L., et al.; Childhood Overgrowth Consortium (2014).
Mutations in the DNAmethyltransferase gene DNMT3A cause
an overgrowth syndrome with intellectual disability. Nat.
Genet. 46, 385–388.
13. Freeman, J.V., Cole, T.J., Chinn, S., Jones, P.R., White, E.M.,
and Preece, M.A. (1995). Cross sectional stature and weight
reference curves for the UK, 1990. Arch. Dis. Child. 73, 17–24.
14. Lek, M., Karczewski, K.J., Minikel, E.V., Samocha, K.E., Banks,
E., Fennell, T., O’Donnell-Luria, A.H., Ware, J.S., Hill, A.J.,
Cummings, B.B., et al.; Exome Aggregation Consortium
(2016). Analysis of protein-coding genetic variation in
60,706 humans. Nature 536, 285–291.
15. Ruark, E., Mu¨nz, M., Renwick, A., Clarke, M., Ramsay, E.,
Hanks, S., Mahamdallie, S., Elliott, A., Seal, S., Strydom, A.,
et al. (2015). The ICR1000 UK exome series: a resource of
gene variation in an outbred population. F1000Res. 4, 883.
16. Kurotaki, N., Stankiewicz, P., Wakui, K., Niikawa, N., and Lup-
ski, J.R. (2005). Sotos syndrome common deletion is mediated
by directly oriented subunits within inverted Sos-REP low-
copy repeats. Hum. Mol. Genet. 14, 535–542.
17. Douglas, J., Tatton-Brown, K., Coleman, K., Guerrero, S., Berg,
J., Cole, T.R., Fitzpatrick, D., Gillerot, Y., Hughes, H.E., Pilz, D.,
et al. (2005). Partial NSD1 deletions cause 5% of Sotos syn-
drome and are readily identifiable by multiplex ligation
dependent probe amplification. J. Med. Genet. 42, e56.
18. Ruark, E., Mu¨nz, M., Clarke, M., Renwick, A., Ramsay, E.,
Elliott, A., Seal, S., Lunter, G., and Rahman, N. (2016). OpEx
- a validated, automated pipeline optimised for clinical exome
sequence analysis. Sci. Rep. 6, 31029.
19. Lunter, G., and Goodson, M. (2011). Stampy: a statistical algo-
rithm for sensitive and fast mapping of Illumina sequence
reads. Genome Res. 21, 936–939.
20. Rimmer, A., Phan, H., Mathieson, I., Iqbal, Z., Twigg, S.R.,
Wilkie, A.O., McVean, G., Lunter, G.; and WGS5002017
Consortium (2014). Integrating mapping-, assembly- and
haplotype-based approaches for calling variants in clinical
sequencing applications. Nat. Genet. 46, 912–918.
21. Mu¨nz, M., Ruark, E., Renwick, A., Ramsay, E., Clarke, M.,
Mahamdallie, S., Cloke, V., Seal, S., Strydom, A., Lunter, G.,
and Rahman, N. (2015). CSN and CAVA: variant annotation
tools for rapid, robust next-generation sequencing analysis
in the clinical setting. Genome Med. 7, 76.
22. Deciphering Developmental Disorders Study (2015). Large-
scale discovery of novel genetic causes of developmental dis-
orders. Nature 519, 223–228.
23. Samocha, K.E., Robinson, E.B., Sanders, S.J., Stevens, C.,
Sabo, A., McGrath, L.M., Kosmicki, J.A., Rehnstro¨m, K., Mal-
lick, S., Kirby, A., et al. (2014). A framework for the interpre-
tation of de novo mutation in human disease. Nat. Genet.
46, 944–950.
24. Reimand, J., Arak, T., Adler, P., Kolberg, L., Reisberg, S., Peter-
son, H., and Vilo, J. (2016). g:Profiler-a web server for func-
tional interpretation of gene lists (2016 update). Nucleic Acids
Res. 44 (W1), W83–W89.
25. Wood, A.R., Esko, T., Yang, J., Vedantam, S., Pers, T.H., Gustafs-
son, S., Chu, A.Y., Estrada, K., Luan, J., Kutalik, Z., et al.;
Electronic Medical Records and Genomics (eMEMERGEGE)
Consortium; MIGen Consortium; PAGEGE Consortium; and
LifeLines Cohort Study (2014). Defining the role of common
variation in the genomic and biological architecture of adult
human height. Nat. Genet. 46, 1173–1186.
26. Lawrence, M.S., Stojanov, P., Mermel, C.H., Robinson, J.T.,
Garraway, L.A., Golub, T.R., Meyerson, M., Gabriel, S.B.,
Lander, E.S., and Getz, G. (2014). Discovery and saturation
analysis of cancer genes across 21 tumour types. Nature 505,
495–501.
27. Cohen, A.S., Tuysuz, B., Shen, Y., Bhalla, S.K., Jones, S.J., and
Gibson, W.T. (2015). A novel mutation in EED associated
with overgrowth. J. Hum. Genet. 60, 339–342.
28. Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H.,
Tempst, P., Jones, R.S., and Zhang, Y. (2002). Role of histone
H3 lysine 27 methylation in Polycomb-group silencing. Sci-
ence 298, 1039–1043.
29. Tatton-Brown, K., Hanks, S., Ruark, E., Zachariou, A., Duarte,
Sdel.V., Ramsay, E., Snape, K., Murray, A., Perdeaux, E.R.,
Seal, S., et al.; Childhood Overgrowth Collaboration (2011).
Germline mutations in the oncogene EZH2 causeWeaver syn-
drome and increased human height. Oncotarget 2, 1127–
1133.
30. Tatton-Brown, K., Douglas, J., Coleman, K., Baujat, G., Cole,
T.R., Das, S., Horn, D., Hughes, H.E., Temple, I.K., Faravelli,
F., et al.; Childhood Overgrowth Collaboration (2005). Geno-
type-phenotype associations in Sotos syndrome: an analysis
of 266 individuals with NSD1 aberrations. Am. J. Hum. Genet.
77, 193–204.
31. Field, M., Tarpey, P.S., Smith, R., Edkins, S., O’Meara, S., Ste-
vens, C., Tofts, C., Teague, J., Butler, A., Dicks, E., et al.
(2007). Mutations in the BRWD3 gene cause X-linked mental
retardation associatedwithmacrocephaly. Am. J. Hum.Genet.
81, 367–374.
32. Cottereau, E., Mortemousque, I., Moizard, M.P., Bu¨rglen, L.,
Lacombe, D., Gilbert-Dussardier, B., Sigaudy, S., Boute, O., Da-
vid, A., Faivre, L., et al. (2013). Phenotypic spectrum of Simp-
son-Golabi-Behmel syndrome in a series of 42 cases with a
mutation in GPC3 and review of the literature. Am. J. Med.
Genet. C. Semin. Med. Genet. 163C, 92–105.The Ame33. Saxena, A., and Sampson, J.R. (2014). Phenotypes associated
with inherited and developmental somatic mutations in
genes encoding mTOR pathway components. Semin. Cell
Dev. Biol. 36, 140–146.
34. Mirzaa, G., Timms, A.E., Conti, V., Boyle, E.A., Girisha, K.M.,
Martin, B., Kircher, M., Olds, C., Juusola, J., Collins, S., et al.
(2016). PIK3CA-associated developmental disorders exhibit
distinct classes of mutations with variable expression and
tissue distribution. JCI insight 1.
35. Barnard, R.A., Pomaville, M.B., and O’Roak, B.J. (2015). Muta-
tions andmodeling of the chromatin Remodeler CHD8 define
an emerging autism etiology. Front. Neurosci. 9, 477.
36. Harshman, S.W., Young, N.L., Parthun, M.R., and Freitas, M.A.
(2013). H1 histones: current perspectives and challenges.
Nucleic Acids Res. 41, 9593–9609.
37. Kalashnikova, A.A., Rogge, R.A., and Hansen, J.C. (2016).
Linker histone H1 and protein-protein interactions. Biochim.
Biophys. Acta 1859, 455–461.
38. Maquat, L.E., and Li, X. (2001). Mammalian heat shock p70
and histone H4 transcripts, which derive from naturally in-
tronless genes, are immune to nonsense-mediated decay.
RNA 7, 445–456.
39. Qiao, Q., Li, Y., Chen, Z., Wang, M., Reinberg, D., and Xu,
R.M. (2011). The structure of NSD1 reveals an autoregulatory
mechanism underlying histone H3K36 methylation. J. Biol.
Chem. 286, 8361–8368.
40. Okano, M., Bell, D.W., Haber, D.A., and Li, E. (1999). DNA
methyltransferases Dnmt3a and Dnmt3b are essential for de
novo methylation and mammalian development. Cell 99,
247–257.
41. Kaneda,M., Okano,M., Hata, K., Sado, T., Tsujimoto, N., Li, E.,
and Sasaki, H. (2004). Essential role for de novo DNA methyl-
transferase Dnmt3a in paternal and maternal imprinting.
Nature 429, 900–903.
42. Engelman, J.A., Luo, J., and Cantley, L.C. (2006). The evolu-
tion of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat. Rev. Genet. 7, 606–619.
43. Chen, W.Y., Shih, H.T., Liu, K.Y., Shih, Z.S., Chen, L.K., Tsai,
T.H., Chen, M.J., Liu, H., Tan, B.C., Chen, C.Y., et al. (2015).
Intellectual disability-associated dBRWD3 regulates gene
expression through inhibition of HIRA/YEM-mediated chro-
matin deposition of histone H3.3. EMBO Rep. 16, 528–538.
44. Katanoda, K. (2016). Neuroblastoma mass screening–what
can we learn from it? J. Epidemiol. 26, 163–165.
45. Lapunzina, P. (2005). Risk of tumorigenesis in overgrowth
syndromes: a comprehensive review. Am. J. Med. Genet. C.
Semin. Med. Genet. 137C, 53–71.
46. Ernst, T., Chase, A.J., Score, J., Hidalgo-Curtis, C.E., Bryant, C.,
Jones, A.V., Waghorn, K., Zoi, K., Ross, F.M., Reiter, A., et al.
(2010). Inactivating mutations of the histone methyltransfer-
ase gene EZH2 in myeloid disorders. Nat. Genet. 42, 722–726.
47. Ntziachristos, P., Tsirigos, A., Van Vlierberghe, P., Nedjic, J.,
Trimarchi, T., Flaherty, M.S., Ferres-Marco, D., da Ros, V.,
Tang, Z., Siegle, J., et al. (2012). Genetic inactivation of the
polycomb repressive complex 2 in T cell acute lymphoblastic
leukemia. Nat. Med. 18, 298–301.
48. Bo¨do¨r, C., Grossmann, V., Popov, N., Okosun, J., O’Riain, C.,
Tan, K., Marzec, J., Araf, S., Wang, J., Lee, A.M., et al. (2013).
EZH2 mutations are frequent and represent an early event in
follicular lymphoma. Blood 122, 3165–3168.
49. Okosun, J., Bo¨do¨r, C., Wang, J., Araf, S., Yang, C.Y., Pan, C.,
Boller, S., Cittaro, D., Bozek, M., Iqbal, S., et al. (2014).rican Journal of Human Genetics 100, 725–736, May 4, 2017 735
Integrated genomic analysis identifies recurrent mutations
and evolution patterns driving the initiation and progression
of follicular lymphoma. Nat. Genet. 46, 176–181.
50. Yang, L., Rau, R., and Goodell, M.A. (2015). DNMT3A in hae-
matological malignancies. Nat. Rev. Cancer 15, 152–165.
51. Cancer Genome Atlas Network (2015). Comprehensive
genomic characterization of head and neck squamous cell car-
cinomas. Nature 517, 576–582.
52. Rauch, A., Wieczorek, D., Graf, E., Wieland, T., Endele, S.,
Schwarzmayr, T., Albrecht, B., Bartholdi, D., Beygo, J., Di Do-
nato, N., et al. (2012). Range of genetic mutations associated
with severe non-syndromic sporadic intellectual disability:
an exome sequencing study. Lancet 380, 1674–1682.
53. de Ligt, J., Willemsen, M.H., van Bon, B.W., Kleefstra, T., Yn-
tema, H.G., Kroes, T., Vulto-van Silfhout, A.T., Koolen, D.A.,736 The American Journal of Human Genetics 100, 725–736, May 4,de Vries, P., Gilissen, C., et al. (2012). Diagnostic exome
sequencing in persons with severe intellectual disability.
N. Engl. J. Med. 367, 1921–1929.
54. Gilissen, C., Hehir-Kwa, J.Y., Thung, D.T., van de Vorst, M.,
van Bon, B.W., Willemsen, M.H., Kwint, M., Janssen, I.M.,
Hoischen, A., Schenck, A., et al. (2014). Genome sequencing
identifies major causes of severe intellectual disability. Nature
511, 344–347.
55. Vissers, L.E., Gilissen, C., and Veltman, J.A. (2016). Genetic
studies in intellectual disability and related disorders. Nat.
Rev. Genet. 17, 9–18.
56. Martinez, F., Caro-Llopis, A., Rosello, M., Oltra, S., Mayo, S.,
Monfort, S., and Orellana, C. (2017). High diagnostic yield
of syndromic intellectual disability by targeted next-genera-
tion sequencing. J. Med. Genet. 54, 87–92.2017
